Latest Asx News

ARC Funds Limited posted a $2.45 million loss for FY2025, driven by strategic investments and increased transaction costs as it expands its funds management platform.

Foresta Group Holdings reported a $3.375 million net loss for FY2025 while making significant progress on its Kawerau biomass facility in New Zealand, securing key approvals, partnerships, and funding. The company aims to commence construction in FY2026, positioning itself in the renewable energy sector.

CTI Logistics Limited has announced a fully franked ordinary dividend of AUD 0.055 per share for the half-year ending June 2025, offering shareholders reinvestment and bonus security plans with attractive discounts.

BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.

BNK Banking Corporation Limited has reported a significant turnaround in its FY25 financial results, driven by margin expansion and a robust capital position. The bank’s strategic portfolio reshaping and disciplined cost management underpin its improved profitability and outlook.

McMillan Shakespeare Limited reported steady FY25 growth with Normalised UNPATA of $103.2 million and an 8.3% dividend yield, underpinned by digital innovation and strategic investments.

Glennon Small Companies Limited reported a robust FY25 with a 232.75% jump in net profit and declared final dividends, while strategically resetting its preference shares amid evolving small-cap market dynamics.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit for FY25, marking the completion of its transformative Simply Stronger program that enhanced digital offerings and customer reach.

The Federal Court of Australia has dismissed Harvey Norman’s appeal against prior legal declarations, setting the stage for an upcoming penalty hearing that could impact the retailer’s future.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.